DONNA PURVIANCE: Open Payments
NPI 1013240597 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$570 in 21 payments from 13 companies in 2025. Trend: 2023 $81 · 2024 $1,559 · 2025 $570
Food & beverage: $570
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 2 | $142 |
| Novartis Pharmaceuticals Corporation | 6 | $140 |
| Eisai Inc. | 3 | $66 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $27 |
| Janssen Biotech, Inc. | 1 | $25 |
| Syndax Pharmaceuticals, Inc. | 1 | $25 |
| Pharmacosmos Therapeutics Inc. | 1 | $24 |
| Merck Sharp & Dohme LLC | 1 | $24 |
| Geron Corporation | 1 | $22 |
| Genentech USA, Inc. | 1 | $20 |
Products named: JEMPERLI, Lenvima, SCEMBLIX, KISQALI, Fabhalta, TALVEY, REVUFORJ, MONOFERRIC.
Industry payments across IN — which companies pay providers there.
